CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.85
+6.03%Oct 28, 2026, 20:05 UTC
Coherus Oncology announced interim clinical data from its TREGCHECK program evaluating tagmokitug with toripalimab, with or without chemotherapy, including a confirmed 75% objective response rate in evaluable first-line ESCC patients regardless of PD-L1 status and 100% among PD-L1-positive patients.
Source:Oct 26, 2026, 13:30 UTC
Coherus Oncology announced that it will release its third-quarter 2026 financial results on November 9, 2026, and hold a conference call and webcast that day.
Source:Oct 14, 2026, 20:30 UTC
Coherus Oncology announced that it will release interim tagmokitug clinical data and host a webcast on October 28, 2026.
Source:Sep 23, 2026, 13:30 UTC
Coherus Oncology retained Oppenheimer & Co. to market its legacy biosimilar assets.
Aug 17, 2026, 21:33 UTC
Coherus Oncology announced a special dividend of contingent value rights (CVRs) to its stockholders, entitling them to net proceeds from the sale of its remaining legacy biosimilar assets.
Aug 17, 2026, 00:00 UTC
Coherus Oncology, Inc. entered into a new $55 million senior secured term loan facility with Innovatus Life Sciences Lending Fund I, LP, fully drawing the Tranche A amount on August 14, 2026, to repay its prior term loan and for working capital.
Aug 5, 2026, 23:11 UTC
Coherus Oncology reported a Q2 2026 loss of $0.19 per share, missing the Zacks Consensus Estimate of $0.08 per share.
Jun 15, 2026, 00:00 UTC
Coherus Oncology, Inc. dismissed Ernst & Young LLP as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP as its new auditor, effective June 12, 2026.